126 related articles for article (PubMed ID: 22189542)
21. Custom-designed MLPA using multiple short synthetic probes: application to methylation analysis of five promoter CpG islands in tumor and urine specimens from patients with bladder cancer.
Serizawa RR; Ralfkiaer U; Dahl C; Lam GW; Hansen AB; Steven K; Horn T; Guldberg P
J Mol Diagn; 2010 Jul; 12(4):402-8. PubMed ID: 20413679
[TBL] [Abstract][Full Text] [Related]
22. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
[TBL] [Abstract][Full Text] [Related]
23. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
24. The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer.
Shao B; Feng Y; Zhang H; Yu F; Li Q; Tan C; Xu H; Ying J; Li L; Yang D; Peng W; Tang J; Li S; Ren G; Tao Q; Xiang T
J Cell Mol Med; 2018 Feb; 22(2):1257-1271. PubMed ID: 29193730
[TBL] [Abstract][Full Text] [Related]
25. IL-8 suppresses E-cadherin expression in nasopharyngeal carcinoma cells by enhancing E-cadherin promoter DNA methylation.
Zhang RL; Peng LX; Yang JP; Zheng LS; Xie P; Wang MY; Huang BJ; Zhao HR; Bao YX; Qian CN
Int J Oncol; 2016 Jan; 48(1):207-14. PubMed ID: 26530812
[TBL] [Abstract][Full Text] [Related]
26. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
[TBL] [Abstract][Full Text] [Related]
27. Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expression in invasive cancers or cancer cell lines.
Jackson P; Millar D; Kingsley E; Yardley G; Ow K; Clark S; Russell PJ
Cancer Lett; 2000 Sep; 157(2):169-76. PubMed ID: 10936677
[TBL] [Abstract][Full Text] [Related]
28. Akt1 as a putative regulator of Hox genes.
Kong KA; Yoon H; Kim MH
Gene; 2013 Jan; 513(2):287-91. PubMed ID: 23154063
[TBL] [Abstract][Full Text] [Related]
29. Relationship between aberrant methylation of FAS promoter and biological behavior of bladder urothelial carcinoma.
Li W; Xia D; Wang Y; Li Y; Xue Y; Wu X; Ye Z
J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):794-798. PubMed ID: 22173501
[TBL] [Abstract][Full Text] [Related]
30. Methylation-mediated silencing of Dlg5 facilitates bladder cancer metastasis.
Zhou Z; Guo Y; Liu Y; Zhang F; Wang Y; Shen B; Qin Y; Qiu J
Exp Cell Res; 2015 Feb; 331(2):399-407. PubMed ID: 25478998
[TBL] [Abstract][Full Text] [Related]
31. Promoter analysis of epigenetically controlled genes in bladder cancer.
Veerla S; Panagopoulos I; Jin Y; Lindgren D; Höglund M
Genes Chromosomes Cancer; 2008 May; 47(5):368-78. PubMed ID: 18196590
[TBL] [Abstract][Full Text] [Related]
32. KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients.
Cebrian V; Fierro M; Orenes-Piñero E; Grau L; Moya P; Ecke T; Alvarez M; Gil M; Algaba F; Bellmunt J; Cordon-Cardo C; Catto J; López-Beltrán A; Sánchez-Carbayo M
Am J Pathol; 2011 Aug; 179(2):540-6. PubMed ID: 21683672
[TBL] [Abstract][Full Text] [Related]
33. High frequency of promoter methylation of the 14-3-3 sigma and CAGE-1 genes, but lack of hypermethylation of the caveolin-1 gene, in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder.
Kunze E; Schlott T
Int J Mol Med; 2007 Oct; 20(4):557-63. PubMed ID: 17786288
[TBL] [Abstract][Full Text] [Related]
34. A 5'-CG-3'-rich region in the promoter of the transcriptionally frequently silenced RET protooncogene lacks methylated cytidine residues.
Munnes M; Patrone G; Schmitz B; Romeo G; Doerfler W
Oncogene; 1998 Nov; 17(20):2573-83. PubMed ID: 9840920
[TBL] [Abstract][Full Text] [Related]
35. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
[TBL] [Abstract][Full Text] [Related]
36. CpG island methylation status in the EpCAM promoter region and gene expression.
Yu G; Zhang X; Wang H; Rui D; Yin A; Qiu G; He Y
Oncol Rep; 2008 Nov; 20(5):1061-7. PubMed ID: 18949402
[TBL] [Abstract][Full Text] [Related]
37. Aberrant Methylation of Suppressor of Cytokine Signaling 1 (SOCS1) Gene as a Biomarker for Early Prediction and Diagnosis of Bladder Cancer.
Guan H; Li X; Lu J; Meng L; Guo Y; Dong J; Rong S; Zhao F; Shen H
Clin Lab; 2020 May; 66(5):. PubMed ID: 32390384
[TBL] [Abstract][Full Text] [Related]
38. Urinary bladder organ hypertrophy is partially regulated by Akt1-mediated protein synthesis pathway.
Qiao LY; Xia C; Shen S; Lee SH; Ratz PH; Fraser MO; Miner A; Speich JE; Lysiak JJ; Steers WD
Life Sci; 2018 May; 201():63-71. PubMed ID: 29572181
[TBL] [Abstract][Full Text] [Related]
39. Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway.
Park S; Kim D; Kaneko S; Szewczyk KM; Nicosia SV; Yu H; Jove R; Cheng JQ
J Biol Chem; 2005 Nov; 280(47):38932-41. PubMed ID: 16174774
[TBL] [Abstract][Full Text] [Related]
40. Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance.
Trifa F; Karray-Chouayekh S; Jmaa ZB; Jmal E; Khabir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
Med Oncol; 2013 Mar; 30(1):418. PubMed ID: 23315218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
